Phase 1 trial shows potential of LM-101 plus rituximab in treating relapsed lymphoma and advanced head and neck cancer, suggesting efficacy for further research.
LM-101 was well tolerated. The preliminary efficacy signal supports further evaluation of LM-101 plus rituximab in relapsed/refractory lymphoma.
No takes yet. Share an insight, caveat, or question.
Cai et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: